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The Next Steps After Deﬁning the Right Tools for
Noninvasive Imaging of CardiotoxicityThomas H. Marwick, MD, PHD, MPH,* Jagat Narula, MD, PHDyT he cardiac effects of treatment for malig-nancy are likely to become an increasingproblem over the coming decades. This issue
is multifactorial and reﬂects the evolution of cancer
from a malignant illness to a chronic disease, as well
as the widespread use of cardiotoxic agents. Two
groups of patients seem to be especially at risk. In
survivors of childhood cancer, the risk for recurrence
or progression of malignancy rapidly diminishes after
a decade, and cardiac complications are the main
cause of cancer-related mortality that is unrelated
to recurrence (1). In adults, several of the most
common malignancies (especially breast cancer and
lymphoma) are often treated with anthracyclines
and/or radiotherapy (2). Breast cancer is the most
common source of cardiac problems, reﬂecting
its frequency, the cardiotoxic effects of speciﬁc
chemotherapy, and the consequences of radiation to
the left breast. Improvements in detection and
therapy have led to >2 million American women
who will have sufﬁcient survival from cancer to
develop complications of cancer chemotherapy (3).
Not only are many patients at risk, but the
development of overt cytotoxic-induced heart
failure is a late manifestation with a substantially
adverse prognosis (4).
This issue of iJACC carries a review that
emphasizes the range of imaging investigations
now available for the diagnosis of cardiac injury (5).
The use of imaging is inherent to the diagnosis
of cardiotoxicity and is usually deﬁned as a
symptomatic ejection fraction (EF) decrement of 5%
or an asymptomatic fall of >10% to an EF of <55% (6).
However, it may be that in addition to the limitationsFrom the *Menzies Research Institute Tasmania, Hobart, Australia; and
the yIcahn School of Medicine at Mount Sinai, New York, New York.of nuclear ventriculography and 2-dimensional
echocardiography, the most widely used methods for
the assessment of cardiotoxicity, the measurement of
EF may itself be insensitive to minor changes in
left ventricular status. Using echocardiography, the
smallest real change of EF that can be detected with
95% conﬁdence is 11%, with documented test-retest
variability of about 12% and intraobserver and
interobserver variability of 6% (7). A good reﬂection
of the practical challenges of applying EF in patients
was reported in the analysis of follow-up EFs in
356 oncology patients undergoing an average of 3
echocardiographic examinations per patient, among
whom 9 abnormal ﬁndings were reported, and no
alteration of treatment was made (8). Some of the
reproducibility challenges of repeated measurements
of a 3-dimensional (3D) object in 2 dimensions
have been addressed by applying inherently 3D
methods, including 3D echocardiography and cardiac
magnetic resonance. These methods are highly
concordant (9) and have high levels of reliability and
lower test-retest variation than 2-dimensional
imaging (10).
The challenging aspect of monitoring these patients
is that dysfunction needs to be detected in a preclinical
stage. This is a situation in which an EF does not
function very well as a prognostic technique, at least in
other diseases. Attention has therefore turned to tools
that show changes in early disease, particularly
measurement of myocardial deformation, either with
speckle-tracking echocardiography or cardiac mag-
netic resonance. Strain changes are antecedent to EF
changes and provide incremental prognostic infor-
mation (11). The present review shows how this
information has been adapted to the cardio-oncology
group (5). Patients developing cardiotoxicity at
6 months were effectively identiﬁed by changes of
strain at 3 months. Other markers that may precede
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852functional changes include edema and metabolic
disturbances. Magnetic resonance imaging has also
been used for the identiﬁcation of anthracycline-
induced changes of aortic stiffness, possibly
responsible for disturbances of ventriculoarterial
impedance.
Unquestionably, better knowledge of the cardiac
complications of cancer should contribute to the pro-
vision of better information to patients regarding car-
diovascular risks during the consent process;
improvement of management decisions on the basis of
the risk for these late effects; as well as adjuvant
therapy, assistance in the planning and delivery
of radiotherapy, and better targeted follow-up,
screening, and intervention for cardiovascular com-
plications (6). The review by Kongbundansuk and
Hundley (5) is very helpful in deﬁning what imaging
tests are available to investigate these issues, but
it is only the ﬁrst step in dealing with this problem.
There are many cancer survivors, and the population-
attributable risk for cardiotoxicity for heart failure
is almost certainly less than that due to age,
hypertension, or diabetes mellitus, for none of
which do we currently run a heart failure screening
program. Keeping in mind that imaging for the
detection of disease in asymptomatic patients is
a common cause of inappropriate use, together
with the need for ongoing screening, as well as
the limited availability and high cost of some
modalities, we must worry that the ﬁeld of cardio-
oncology has a risk for low return for a lot of imaging
investment.
What we now need are clinical studies to address
why, when, and how often to image in cancer survi-
vors. Current follow-up protocols are based on valu-
able experience (12), but they are not evidence based
and are determined in large part by level of exposure.More sophisticated algorithms are needed to quantify
heart failure risk, perhaps including other heart
failure risk factors and/or biomarkers. Patients
without troponin I leakage rarely develop reductions
of left ventricular EF, whereas those with troponin I
leakage have deteriorations of EF that are
proportionate to both the extent of the leakage as
well as its duration (13). Indeed, the likelihood of
recovery from reduction of EF in patients receiving
trastuzumab has been linked to the degree of
troponin I elevation (14).
The potential responses to this problem of car-
diotoxicity include prevention, treatment, and pro-
phylaxis. In terms of prevention, avoidance of
concurrent treatment with anthracyclines and tyro-
sine kinase inhibitors appears to be desirable. The cu-
mulative dose of anthracyclines needs to be carefully
monitored, and there is some evidence for effective
cardioprotection with other agents such as dexrazox-
ane (6). The desirability of the side-effect burden of
uniform (or even widespread) use of cardioprotective
medication seems questionable. However, the
detection of early left ventricular dysfunction may
permit a more focused use of cardioprotective
therapy, of which there are a number of options (15).
Thus, numerous potential strategies may be used to
reduce the frequency and the magnitude of
cardiotoxic responses. The review of Kongbundansuk
and Hundley (5) reminds us that we have the tools.
We need more clinical studies to better understand
why to select one over another and when and how
often to use them.
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